DK2014652T3 - Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor - Google Patents

Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor

Info

Publication number
DK2014652T3
DK2014652T3 DK07742334.1T DK07742334T DK2014652T3 DK 2014652 T3 DK2014652 T3 DK 2014652T3 DK 07742334 T DK07742334 T DK 07742334T DK 2014652 T3 DK2014652 T3 DK 2014652T3
Authority
DK
Denmark
Prior art keywords
activator
activated
peroxisom
proliferator
peroxisom proliferator
Prior art date
Application number
DK07742334.1T
Other languages
English (en)
Inventor
Shogo Sakuma
Nobutaka Mochiduki
Masatoshi Ushioda
Rie Takahashi
Tomio Yamakawa
Seiichiro Masui
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Application granted granted Critical
Publication of DK2014652T3 publication Critical patent/DK2014652T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07742334.1T 2006-04-18 2007-04-18 Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor DK2014652T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006114561 2006-04-18
PCT/JP2007/058899 WO2007119887A1 (ja) 2006-04-18 2007-04-18 ペルオキシソーム増殖剤活性化受容体δの活性化剤

Publications (1)

Publication Number Publication Date
DK2014652T3 true DK2014652T3 (da) 2014-10-13

Family

ID=38609637

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07742334.1T DK2014652T3 (da) 2006-04-18 2007-04-18 Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor

Country Status (22)

Country Link
US (2) US8404726B2 (da)
EP (1) EP2014652B1 (da)
JP (3) JP5290749B2 (da)
KR (1) KR101507173B1 (da)
CN (2) CN102643248A (da)
AU (1) AU2007239283B2 (da)
BR (1) BRPI0710266B8 (da)
CA (1) CA2649735C (da)
CY (1) CY1115637T1 (da)
DK (1) DK2014652T3 (da)
ES (1) ES2522291T3 (da)
IL (1) IL194847A (da)
MX (1) MX2008013292A (da)
MY (1) MY154836A (da)
NO (1) NO341476B1 (da)
NZ (1) NZ572268A (da)
PL (1) PL2014652T3 (da)
PT (1) PT2014652E (da)
RU (1) RU2435764C2 (da)
SI (1) SI2014652T1 (da)
WO (1) WO2007119887A1 (da)
ZA (1) ZA200809148B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5290749B2 (ja) 2006-04-18 2013-09-18 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2277874B1 (en) 2008-04-15 2018-06-27 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2791914C (en) * 2010-03-05 2019-01-15 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN103402359B (zh) 2011-01-17 2016-08-24 卡尔约药物治疗公司 含烯烃核运输调节剂及其用途
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
PE20141003A1 (es) 2011-07-29 2014-09-02 Karyopharm Therapeutics Inc Moduladores del transporte nuclear y usos de los mismos
TWI574957B (zh) 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2858991T (pt) 2012-05-09 2018-12-17 Biogen Ma Inc Moduladores do transporte nuclear e usos dos mesmos
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
EP2981522A4 (en) 2013-04-05 2016-08-31 Salk Inst For Biological Studi PPAR AGONISTS
AU2014284168B2 (en) 2013-06-21 2018-10-25 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
GB2534052A (en) * 2013-08-30 2016-07-13 Council Scient Ind Res Pyrazolochalcones as potential anticancer agents
MX388170B (es) 2014-08-15 2025-03-19 Karyopharm Therapeutics Inc Polimorfos de selinexor
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
EP3317249A1 (en) 2015-07-02 2018-05-09 The Medical College of Wisconsin, Inc. Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors
ES2988059T3 (es) 2015-10-07 2024-11-19 Astellas Eng Small Molecules Us Incorporated Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
JP6925367B2 (ja) 2016-04-13 2021-08-25 ミトブリッジ,インコーポレーテッド Pparアゴニスト、化合物、医薬組成物、及びその使用方法
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
JP7305548B2 (ja) * 2017-11-15 2023-07-10 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体活性化剤

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956379A (en) 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
KR100436812B1 (ko) 1995-01-06 2004-08-31 도레이 가부시끼가이샤 벤젠축합헤테로환유도체및그유도체를유효성분으로함유하는의약조성물
CA2171702A1 (en) 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
WO1996035688A1 (en) 1995-05-08 1996-11-14 Nippon Chemiphar Co., Ltd. 2,4-thiazolidinedione or oxazolidinedione derivatives and hypoglycemic agent
ATE216384T1 (de) 1996-01-22 2002-05-15 Fujisawa Pharmaceutical Co Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
US20020032330A1 (en) 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
JP4427825B2 (ja) 1997-07-24 2010-03-10 アステラス製薬株式会社 コレステロール低下作用を有する医薬組成物
US6589969B1 (en) 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DK1206457T3 (da) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
EP1310494B1 (en) 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1368011A1 (en) 2001-02-22 2003-12-10 SmithKline Beecham Corporation Method for treating ppar gamma mediated diseases
JP4157381B2 (ja) 2001-03-23 2008-10-01 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体の活性化剤
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
BRPI0211844B8 (pt) * 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
OA12653A (en) * 2001-08-29 2006-06-16 Warner Lambert Co Oral antidiabetic agents.
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
CN1293076C (zh) 2001-10-12 2007-01-03 日本化学医药株式会社 过氧化物酶体增殖剂应答性受体δ的活化剂
JP2003292439A (ja) 2002-02-04 2003-10-15 Sumitomo Pharmaceut Co Ltd 新規ピロール誘導体からなるppar活性化剤
JP2005529077A (ja) * 2002-02-25 2005-09-29 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体調節物質
EP1513817A1 (en) 2002-05-24 2005-03-16 Takeda Pharmaceutical Company Limited 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity
AU2003281040A1 (en) 2002-07-10 2004-02-02 Sumitomo Pharmaceuticals Co., Ltd. Biaryl derivatives
US6800655B2 (en) 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
BR0313946A (pt) * 2002-08-30 2005-07-12 Hoffmann La Roche Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método
EP1535915A4 (en) 2002-09-06 2005-10-05 Takeda Pharmaceutical FURANOIC OR THIOPHENE DERIVATIVES AND THEIR MEDICAL USE
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
WO2004092131A1 (en) 2003-01-06 2004-10-28 Eli Lilly And Company Indole derivatives as ppar modulators
WO2004063184A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Thiophene derivative ppar modulators
WO2004063165A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company A pyrazole derivative as ppar modulator
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
JPWO2005054213A1 (ja) 2003-12-02 2007-12-06 塩野義製薬株式会社 ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
GB0403148D0 (en) 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
FR2869611B1 (fr) 2004-05-03 2006-07-28 Merck Sante Soc Par Actions Si Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
WO2005115384A2 (en) 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
WO2006125324A1 (en) 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
BRPI0612396A2 (pt) 2005-07-06 2016-09-06 Nippon Chemiphar Co composto ou um sal do mesmo, e, ativador para receptor ativado por proliferador de peroxissoma delta
JP5290749B2 (ja) 2006-04-18 2013-09-18 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
JPWO2008016175A1 (ja) 2006-08-03 2009-12-24 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体の活性化剤

Also Published As

Publication number Publication date
KR20090006853A (ko) 2009-01-15
JP6049791B2 (ja) 2016-12-21
JP2013067652A (ja) 2013-04-18
JP5290749B2 (ja) 2013-09-18
CN102643248A (zh) 2012-08-22
US20130217734A1 (en) 2013-08-22
EP2014652A4 (en) 2010-10-06
PL2014652T3 (pl) 2015-02-27
PT2014652E (pt) 2014-11-12
US20090298896A1 (en) 2009-12-03
NO341476B1 (no) 2017-11-27
NZ572268A (en) 2011-09-30
EP2014652A1 (en) 2009-01-14
JPWO2007119887A1 (ja) 2009-08-27
CA2649735A1 (en) 2007-10-25
WO2007119887A1 (ja) 2007-10-25
HK1135377A1 (en) 2010-06-04
US8404726B2 (en) 2013-03-26
SI2014652T1 (sl) 2014-12-31
IL194847A (en) 2013-10-31
BRPI0710266B8 (pt) 2021-05-25
AU2007239283A1 (en) 2007-10-25
MX2008013292A (es) 2008-11-14
CN101466687B (zh) 2012-04-11
CN101466687A (zh) 2009-06-24
RU2008145505A (ru) 2010-05-27
JP5782016B2 (ja) 2015-09-24
CA2649735C (en) 2016-02-09
MY154836A (en) 2015-07-31
NO20084856L (no) 2008-12-29
RU2435764C2 (ru) 2011-12-10
EP2014652B1 (en) 2014-08-06
JP2015163611A (ja) 2015-09-10
KR101507173B1 (ko) 2015-03-30
BRPI0710266B1 (pt) 2020-07-14
ZA200809148B (en) 2010-01-27
CY1115637T1 (el) 2017-01-04
BRPI0710266A2 (pt) 2012-02-28
ES2522291T3 (es) 2014-11-14
AU2007239283B2 (en) 2013-02-07
IL194847A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
DK2014652T3 (da) Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor
EP2087096A4 (en) MODIFIED CYANOBACTERIA
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
DE602006004717D1 (de) Kapselperforationsmodul
DE602007002544D1 (de) Nuancierungsmittel
DE602007008423D1 (de) Flüssigkeitshärtung
DE602007009267D1 (de) Reifenaufblasverfahren
DE602007003893D1 (de) Kippambossanordnung
AT504580A3 (de) Scan-einrichtung
DE602007006947D1 (de) Pyridopyrimidinonderivate
DE602007000258D1 (de) Kassetteneinspannmechanismus
ATE524477T1 (de) Aziridinylepothilonverbindungen
DE602007008400D1 (de) Kaliummonopersulfatlösungen
DE502007001629D1 (de) Rfahren
DE602006020192D1 (de) Riemenscheibenanorndung
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007000501D1 (de) Breitbandrichtkoppler
DE602007001098D1 (de) Spindelmäheinheit
DE602007010544D1 (de) Motorstatorstruktur
DE602007004080D1 (de) Tintenstrahlaufnehmer
DE602007007460D1 (de) Sehkrafttestsystem
DE502007000361D1 (de) Stanznieteinheit
DE602007000333D1 (de) Napfbefestigungsvorrichtung